Australia's sunscreen reviews address two different questions

What was put forward

The Therapeutic Goods Administration ran a consultation from March 26 to May 23 on possible improvements to sunscreen regulation. Its options included stronger oversight of testing laboratories, more reliable and transparent SPF testing, timelier adoption of new test methods, periodic quality checks, ingredient standards, and simpler labeling.

Why the process matters

A sunscreen label compresses a large amount of formulation and testing work into a few claims. Regulation determines which test methods count, how evidence is documented, and what happens when products or laboratories fall short.

The broader consultation page checked September 15 lists the consultation as closed on May 23; no final response was found on that page. That is a page-specific observation, not proof that every Australian sunscreen policy remains unchanged.

A separate ingredient-safety consultation

On September 11, the TGA opened a separate consultation on 4-methylbenzylidene camphor (4-MBC). It closes October 12, 2026, ahead of advisory-committee consideration in November. October 12 is the closing date, not an opening or implementation date.

The TGA Delegate put forward two options using concentration limits and, for one option, age and application-site conditions. Two private applicants proposed a prohibition. These are competing proposals, not adopted restrictions; the applicants' proposal should not be described as a TGA ban.

The TGA's September 11 announcement advises Australians to continue sunscreen use alongside other sun-protection measures. It does not announce a product recall. This ingredient-specific process is separate from the earlier review of SPF testing and broader regulation.

What the safety review can establish

The July-version report, published September 11, combines existing safety assessments and toxicology with the Australian Sunscreen Exposure Model. Its recommendations depend on assumed exposure and available evidence, not a newly measured rate of disease among sunscreen users. It lacked full raw data for independent corroboration and excluded other consumer-product exposure, metabolites and impurities from its risk assessment.

CTX grades the policy process, not sunscreen efficacy or a product's safety. Our sources are regulator records, not a sponsored product trial; private applicants' proposals are identified as such. Sources for this clarification checked September 15, 2026. The September 11 development is not being presented as a new September 15 action.